Gene Editing News and Research

RSS

UH researcher set to explore how testosterone works in the brain

Most people have some idea about the hormone testosterone –how it regulates male behavior or how too little of it might cause a decrease in libido and too much might cause aggressive and irritable behavior. Turns out, no one yet knows how testosterone really does all that.

16 Aug 2021

Novel CRISPR-based technique could inspire a new class of medical diagnostics

Scientists have repurposed the genetic modification technology CRISPR to identify antibodies in patient blood samples in a move that could inspire a new class of medical diagnostics in addition to a host of other applications.

13 Aug 2021

VPS29 gene facilitates coronavirus cell entry

In a research paper recently uploaded to the bioRxiv* preprint server by Poston et al. (August 8th, 2021), common host factors amongst several zoonotic pathogens are explored by CRISPR-Cas9 screening in human lung cells, focusing in particular on the betacoronavirus genus.

11 Aug 2021

Researchers use prime editing to correct cystic fibrosis in cultured human stem cells

Researchers from the group of Hans Clevers (Hubrecht Institute) corrected mutations that cause cystic fibrosis in cultured human stem cells.

9 Aug 2021

Scientists identify new therapeutic target for several aggressive cancers

A protein in tumor cells could be targeted to treat some types of aggressive cancer including brain, blood, skin, and kidney, new research has shown.

4 Aug 2021

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; "Rigaku"), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”)

From Rigaku Corporation 4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Start codon disruption with CRISPR-Cas9 gene editing prevents Fuchs’ corneal dystrophy in mice

In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' corneal dystrophy in mice.

3 Aug 2021

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer's development

Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer's development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center.

28 Jul 2021

New insights on replication-stress sensitivity in breast cancer cells

Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1.

28 Jul 2021

Researchers develop ovarian tumor microenvironment-chip to test novel ways to treat the disease

In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body.

23 Jul 2021

Study: Gene editing therapy for early-stage Huntington’s disease may have long-lasting benefits

In a new study on mice, Johns Hopkins Medicine researchers report that using MRI scans to measure blood volume in the brain can serve as a noninvasive way to potentially track the progress of gene editing therapies for early-stage Huntington's disease, a neurodegenerative disorder that attacks brain cells.

7 Jul 2021

Gene-edited cellular therapeutics can successfully treat cardiovascular and pulmonary diseases

Scientists at UC San Francisco have shown that gene-edited cellular therapeutics can be used to successfully treat cardiovascular and pulmonary diseases, potentially paving the way for developing less expensive cellular therapies to treat diseases for which there are currently few viable options.

6 Jul 2021

RNA-binding proteins represent a new class of drug targets for triple-negative breast cancer

In cancer research, it's a common goal to find something about cancer cells -- some sort of molecule -- that drives their ability to survive, and determine if that molecule could be inhibited with a drug, halting tumor growth. Even better: The molecule isn't present in healthy cells, so they remain untouched by the new therapy.

2 Jul 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

1 Jul 2021

Researchers develop engineered yeast probiotic for treatment of inflammatory bowel disease

The world of microbes living in the human gut can have far-reaching effects on human health. Multiple diseases, including inflammatory bowel disease (IBD), are tied to the balance of these microbes, suggesting that restoring the right balance could help treat disease.

28 Jun 2021

Gene Editing News and Research

UH researcher set to explore how testosterone works in the brain

Novel CRISPR-based technique could inspire a new class of medical diagnostics

VPS29 gene facilitates coronavirus cell entry

Researchers use prime editing to correct cystic fibrosis in cultured human stem cells

Scientists identify new therapeutic target for several aggressive cancers

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Next-generation CRISPR tools and therapies improved by modified RNA guides

Start codon disruption with CRISPR-Cas9 gene editing prevents Fuchs’ corneal dystrophy in mice

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer's development

New insights on replication-stress sensitivity in breast cancer cells

Researchers develop ovarian tumor microenvironment-chip to test novel ways to treat the disease

Study: Gene editing therapy for early-stage Huntington’s disease may have long-lasting benefits

Gene-edited cellular therapeutics can successfully treat cardiovascular and pulmonary diseases

RNA-binding proteins represent a new class of drug targets for triple-negative breast cancer

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement

Researchers develop engineered yeast probiotic for treatment of inflammatory bowel disease

Olympus Wins a 2021 Edison Award for Automated Cell Culture System

Study introduces a new, improved CRISPR 3.0 system in plants

PerkinElmer to buy SIRION Biotech

Heidelberg researchers replicate rare genetic defect in fish model

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News